12 for digital subtraction angiography in azotaemic patients,” Nephrology Dialysis Transplantation, vol. 19, no. 10, pp. 2526–2531, 2004. [114] C. Briguori, A. Colombo, F. Airoldi et al., “Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures,” Catheterization and Cardiovas- cular Interventions, vol. 67, no. 2, pp. 175–180, 2006. [115] P. S. Reed, S. R. Dixon, J. A. Boura, W. W. O’Neill, and J. K. Kahn, “Comparison of the usefulness of gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography,” American Journal of Cardiology, vol. 100, no. 7, pp. 1090– 1093, 2007. [116] T. F. Boyden and H. S. Gurm, “Does gadolinium-based angiography protect against contrast-induced nephropathy? A systematic review of the literature,” Catheterization and Cardiovascular Interventions, vol. 71, no. 5, pp. 687–693, 2008. [117] A. J. Gauden, P. M. Phal, and K. J. Drummond, “MRI safety; nephrogenic systemic ﬁbrosis and other risks,” Journal of Clinical Neuroscience, vol. 17, no. 9, pp. 1097–1104, 2010. [118] M. R. Prince, H. L. Zhang, G. H. Roditi et al., “Risk factors for NSF: a literature review,” Journal of Magnetic Resonance Imaging, vol. 30, no. 6, pp. 1298–1308, 2009. Cardiology Research and Practice